Published in Hematology Week, April 26th, 2010
BCL6 is the most commonly involved oncogene in diffuse large B cell lymphomas (DLBCL). Previous work has shown that BCL6 is required for survival of lymphoma cells and that blockade of the gene potently kills DLBCL cells. However, although BCL6 it a very attractive therapeutic target, it has not been considered to be particularly amenable to targeting with small molecules.
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2010-04-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.